Ignite Creation Date:
2025-12-24 @ 2:49 PM
Ignite Modification Date:
2026-03-29 @ 8:03 PM
Study NCT ID:
NCT00064259
Status:
TERMINATED
Last Update Posted:
2021-02-17
First Post:
2003-07-08
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer
Sponsor:
National Cancer Institute (NCI)
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Adenocarcinoma of the Esophagus | View |
| None | Adenocarcinoma of the Gastroesophageal Junction | View |
| None | Diffuse Adenocarcinoma of the Stomach | View |
| None | Intestinal Adenocarcinoma of the Stomach | View |
| None | Mixed Adenocarcinoma of the Stomach | View |
| None | Recurrent Esophageal Cancer | View |
| None | Recurrent Gastric Cancer | View |
| None | Squamous Cell Carcinoma of the Esophagus | View |
| None | Stage III Esophageal Cancer | View |
| None | Stage IIIA Gastric Cancer | View |
| None | Stage IIIB Gastric Cancer | View |
| None | Stage IIIC Gastric Cancer | View |
| None | Stage IV Esophageal Cancer | View |
| None | Stage IV Gastric Cancer | View |
Keywords: